drugset / Trial / NCT03468777

A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants

NCT03468777

Phase 1 Terminated 18 enrolled Janssen Research & Development, LLC
RandomizedCrossoverOpen-labelOther

Summary

The main purpose of study is to evaluate the effect of multiple-dose administration of lansoprazole (and optional: time-separated single dose administration of ranitidine) on the pharmacokinetics (PK) of JNJ-63549109 after a single dose of lumicitabine in healthy adult participants, under fasted (and optional: fed) conditions.

Timeline

Start
2018-03-06
Primary completion
2018-07-09
Completion
2018-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lansoprazole Other / unclassified 30 mg Oral
Subject Lumicitabine Small molecule 1000 mg Oral
Subject Ranitidine Unknown 150 mg Oral

Indications

No indication recorded.